menu
    • menu
    [{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Hanlim Pharmaceuticals Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Hanlim Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Hanlim Pharmaceutical"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Hanlim Pharmaceuticals Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Hanlim Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Hanlim Pharmaceutical"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Hanlim Pharmaceuticals Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Acebrophylline","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Hanlim Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Hanlim Pharmaceutical"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Vitis Vinifera Seed Dreid Extract","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Vitis Vinifera Seed Dreid Extract","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"HL237","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Acebrophylline","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"HL301","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rosuvastatin Calcium","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"HL237","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Luminomark","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ezetimibe","moa":"Niemann-Pick C1-like protein 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etodolac","moa":"Cyclooxygenase-2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Hanlim Pharmaceuticals Inc

    Menu

    Hanlim Pharmaceuticals Inc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vonoprazan Fumarate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Bioequivalence of Vonopzan Tablet 20mg(Vonoprazan Fumarate) and Vocinti Tablet 20mg in H...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 15, 2024

                            Lead Product(s) : Vonoprazan Fumarate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rosuvastatin Calcium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Bioequivalence of "Crecheck Tablet 2.5 mg (Rosuvastatin Calcium)" and "Crestor Tablet 5 ...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 26, 2024

                            Lead Product(s) : Rosuvastatin Calcium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acebrophylline

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate Efficacy and Safety of Bronpass Tab. in Patients With Chronic Obstructive Pulmonary Disease

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 30, 2024

                            Lead Product(s) : Acebrophylline

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Recipient : CHA University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of Efficacy and Ocular Surface Assessment Between BRIDIN-plus and Combigan in Glaucoma or Ocular Hy...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 12, 2023

                            Lead Product(s) : Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Recipient : CHA University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acebrophylline

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase IV

                            Recipient : Kwang-Ha Yoo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Efficacy and Safety of Acute Bronchitis Symptoms Improvement for Bronpass Tab. Compared to Erdos ...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 14, 2023

                            Lead Product(s) : Acebrophylline

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase IV

                            Recipient : Kwang-Ha Yoo

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vitis Vinifera Seed Dreid Extract

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate Efficacy and Safety of Entelon 50mg in Patients With Non-Proliferative Diabetic Retinopathy

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            May 03, 2022

                            Lead Product(s) : Vitis Vinifera Seed Dreid Extract

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vitis Vinifera Seed Dreid Extract

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 4 Study to Evaluate Efficacy and Safety of Entelon Tab.150mg in Patients With Chronic Venous Disease(CVD...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            May 11, 2021

                            Lead Product(s) : Vitis Vinifera Seed Dreid Extract

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etodolac

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Safety and PK of LODIENT Tablet 80/2.5mg in Healthy Adult Volunteers

                            Details : Undisclosed

                            Product Name : Lodine

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 16, 2020

                            Lead Product(s) : Etodolac

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ezetimibe

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients Wit...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 09, 2020

                            Lead Product(s) : Ezetimibe

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed

                            Hanlim Pharmaceuticals Inc

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Recipient : CHA University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN-T Eye Drops 0.15% and ALPHAGAN-P E...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 01, 2020

                            Lead Product(s) : Brimonidine Tartrate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Recipient : CHA University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth